Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.

MLA

Eikelboom, John W., et al. “Colchicine and the Combination of Rivaroxaban and Aspirin in Patients Hospitalised with COVID-19 (ACT): An Open-Label, Factorial, Randomised, Controlled Trial.” The Lancet. Respiratory Medicine, vol. 10, no. 12, Dec. 2022, pp. 1169–77. EBSCOhost, https://doi.org/10.1016/S2213-2600(22)00298-3.

APA

Eikelboom, J. W., Jolly, S. S., Belley-Cote, E. P., Whitlock, R. P., Rangarajan, S., Xu, L., Heenan, L., Bangdiwala, S. I., Luz Diaz, M., Diaz, R., Yusufali, A., Kumar Sharma, S., Tarhuni, W. M., Hassany, M., Avezum, A., Harper, W., Wasserman, S., Almas, A., Drapkina, O., … Yusuf, S. (2022). Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet. Respiratory Medicine, 10(12), 1169–1177. https://doi.org/10.1016/S2213-2600(22)00298-3

Chicago

Eikelboom, John W, Sanjit S Jolly, Emilie P Belley-Cote, Richard P Whitlock, Sumathy Rangarajan, Lizhen Xu, Laura Heenan, et al. 2022. “Colchicine and the Combination of Rivaroxaban and Aspirin in Patients Hospitalised with COVID-19 (ACT): An Open-Label, Factorial, Randomised, Controlled Trial.” The Lancet. Respiratory Medicine 10 (12): 1169–77. doi:10.1016/S2213-2600(22)00298-3.